Personalised Cancer Medicine Flashcards 2025
Indications determined by the organ of origin
Ovarian Cancer
Standard
Recommended
Currently not recommended
- BRCA1 y BRCA2*
- Homologous Recombination Deficiency (HRD)
- NGS**
- p53, PD-1/PDL-1, ATM, BARD1, BRIP1, CHECK1, CHECK2, FAM175A, MRE11A, NBN, PALB2, RAD51C, RAR51D.
* germ-line or somatic
** approved in US as companion diagnostics for some PAPR inhibitors
The Standard category is based on current treatment indications with approved funding by the Spanish National Health System.
The Recommended category is based on currentrecommendations by EMEA and FDA.
The Recommended category is based on currentrecommendations by EMEA and FDA.
References:
1. NCCN Guidelines Version 3.2025 Breast, Ovarian, Pancreatic, and Prostate Cancer Genetic Assessment.
2. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. González-Martín, A. et al. Annals of Oncology, Volume 34, Issue 10, 833 - 848.
3. Oaknin A, Guarch R, Barretina P, et al. Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2018 Mar;20(3):274-285. doi: 10.1007/s12094-017-1719-x.
